GI-CORONA The Gastrointestinal Biocorona: The Missing Link in Lipid Digestion and Oral Drug Delivery
- Coordinator
- Universite De Fribourg, Switzerland
- Runs
- 1 January 2027 to 31 December 2031
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101302803
What the project is doing
In the project's own words, from its summary on CORDIS.
Every foreign material that enters the human body is rapidly covered by biomolecules. This ‘biocorona’ has revolutionized our understanding of drug delivery in plasma. Yet, it has rarely been studied for one of the most complex biochemical environments: the gastrointestinal (GI) tract. Evidence for GI-corona formation on lipids and lipid-based drug delivery systems (LBDDSs) is still missing to date, although it could be equally transformative for our understanding of lipid digestion and oral drug delivery.
GI-CORONA will i) provide the first quantitative composition of the GI-corona on dietary lipids and LBDDSs, ii) unravel its hidden effects on lipid digestion, and iii) optimize LBDDS formulations by accounting for the GI-corona. The recent advances in proteomics will be exploited to gain quantitative insights in GI-corona composition from the gastric to the intestinal stage. Current lipid digestion and drug delivery models, which omit most GI biomolecules, will be refined with relevant GI biomolecules to provide more predictive digestion models.
Ultimately, the drug delivery potential from LBDDSs will be optimized accounting for GI-corona formation using biorelevant in vitro intestinal multi-cell models. The expected outcomes are: (i) a robust methodology for corona analysis on liquid lipids, ii) the first comprehensive dataset of GI-corona protein and lipid composition; (iii) next-generation in vitro digestion models with higher predictive power; and (iv) optimized design criteria for LBDDSs for more effective oral drug delivery.
By uncovering this hidden layer of biological interaction, GI-CORONA will transform our understanding of lipid digestion and oral drug delivery, bridging fundamental biophysics, nutrition, and pharmaceutical science.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universite De Fribourg | Fribourg | Switzerland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI